Correlation and prognostic significance of beta-galactoside alpha-2,6-sialyltransferase and serum monosialylated alpha-fetoprotein in hepatocellular carcinoma

World Journal of Gastroenterology

Volumn 11, Issue 42, 2005, Pages 6701-6706

  Poon, Terence C W ^a   Chiu, Clarissa H S ^a   Lai, Paul B S ^a   Mok, Tony S K ^a   Zee, Benny ^a   Chan, Anthony T C ^a   Sung, Joseph J Y ^a   Johnson, Philip J ^b  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

Alpha fetoprotein; Beta galactoside alpha 2,6 sialyltransferase; Cell differentiation; Hepatocellular carcinoma; Patient survival

Indexed keywords

ALPHA FETOPROTEIN; BETA GALACTOSIDE; BETA GALACTOSIDE ALPHA 2,6 SIALYLTRANSFERASE; SIALYLTRANSFERASE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER SURVIVAL; CELL DIFFERENTIATION; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; ENZYME ACTIVITY; FEMALE; HUMAN; HUMAN TISSUE; LIVER CELL CARCINOMA; MALE; PREOPERATIVE EVALUATION; PROGNOSIS;

EID: 30444438409     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v11.i42.6701     Document Type: Article

References (26)

1. Collard JG, Schijven JF, Bikker A, La Riviere G, Bolscher JG, Roos E. Cell surface sialic acid and the invasive and metastatic potential of T-cell hybridomas. Cancer Res 1986; 46: 3521-3527
2. Le Marer N, Laudet V, Svensson EC, Cazlaris H, Van Hille B, Lagrou C, Stehelin D, Montreuil J, Verbert A, Delannoy P. The c-Ha-ras oncogene induces increased expression of beta-galactoside alpha-2, 6-sialyltransferase in rat fibroblast (FR3T3) cells. Glycobiology 1992; 2: 49-56
3. Zhu Y, Srivatana U, Ullah A, Gagneja H, Berenson CS, Lance P. Suppression of a sialyltransferase by antisense DNA reduces invasiveness of human colon cancer cells in vitro. Biochim Biophys Acta 2001; 1536: 148-160
4. Dall'Olio F, Malagolini N, Serafini-Cessi F. Enhanced CMP-NeuAc:Gal beta 1,4GlcNAc-R alpha 2,6 sialyltransferase activity of human colon cancer xenografts in athymic nude mice and of xenograft-derived cell lines. Int J Cancer 1992; 50: 325-330
5. Bresalier RS, Ho SB, Schoeppner HL, Kim YS, Sleisenger MH, Brodt P, Byrd JV. Enhanced sialylation of mucin-associated carbohydrate structures in human colon cancer metastasis. Gastroenterology 1996; 110: 1354-1367
6. Recchi MA, Hebbar M, Hornez L, Harduin-Lepers A, Peyrat JP, Delannoy P. Multiplex reverse transcription polymerase chain reaction assessment of sialyltransferase expression in human breast cancer. Cancer Res 1998; 58: 4066-4070
7. Wang PH, Li YF, Juang CM, Lee YR, Chao HT, Tsai YC, Yuan CC. Altered mRNA expression of sialyltransferase in squamous cell carcinomas of the cervix. Gynecol Oncol 2001; 83: 121-127
8. Fukushima K, Hara-Kuge S, Seko A, Ikehara Y, Yamashita K. Elevation of alpha2-->6 sialyltransferase and alpha1-->2 fucosyltransferase activities in human choriocarcinoma. Cancer Res 1998; 58: 4301-4306
9. Yamamoto H, Oviedo A, Sweeley C, Saito T, Moskal JR. Alpha2,6-sialylation of cell-surface N-glycans inhibits glioma formation in vivo. Cancer Res 2001; 61: 6822-6829
10. Johnson PJ, Portmann B, Williams R. Alpha-fetoprotein concentrations measured by radioimmunoassay in diagnosing and excluding hepatocellular carcinoma. Br Med J 1978; 2: 661-663
11. Sheu JC, Sung JL, Chen DS, Yang PM, Lai MY, Lee CS, Hsu HC, Chuang CN, Yang PC, Wang TH. Growth rate of asymptomatic hepatocellular carcinoma and its clinical implications. Gastroenterology 1985; 89: 259-266
12. Nomura F, Ohnishi K, Tanabe Y. Clinical features and prognosis of hepatocellular carcinoma with reference to serum alpha-fetoprotein levels. Analysis of 606 patients. Cancer 1989; 64: 1700-1707
13. Lok AS, Lai CL. alpha-Fetoprotein monitoring in Chinese patients with chronic hepatitis B virus infection: role in the early detection of hepatocellular carcinoma. Hepatology 1989; 9: 110-115
14. Okuda K. Early recognition of hepatocellular carcinoma. Hepatology 1986; 6: 729-738
15. Trevisani F, D'Intino PE, Morselli-Labate AM, Mazzella G, Accogli E, Caraceni P, Domenicali M, De Notariis S, Roda E, Bernardi M. Serum alpha-fetoprotein for diagnosis of hepatocellular carcinoma in patients with chronic liver disease: influence of HBsAg and anti-HCV status. J Hepatol 2001; 34: 570-575
16. Johnson PJ, Poon TCW, Hjelm NM, Ho CS, Ho SK, Welby C, Stevenson D, Patel T, Parekh R, Townsend RR. Glycan composition of serum alpha-fetoprotein in patients with hepatocellular carcinoma and non-seminomatous germ cell tumour. Br J Cancer 1999; 81: 1188-1195
17. Johnson PJ, Poon TC, Hjelm NM, Ho CS, Blake C, Ho SK. Structures of disease-specific serum alpha-fetoprotein isoforms. Br J Cancer 2000; 83: 1330-1337
18. Poon TC, Mok TS, Chan AT, Chan CM, Leong V, Tsui SH, Leung TW, Wong HT, Ho SK, Johnson PJ. Quantification and utility of monosialylated alpha-fetoprotein in the diagnosis of hepatocellular carcinoma with nondiagnostic serum total alpha-fetoprotein. Clin Chem 2002; 48: 1021-1027
19. Pousset D, Piller V, Bureaud N, Monsigny M, Piller F. Increased alpha2,6 sialylation of N-glycans in a transgenic mouse model of hepatocellular carcinoma. Cancer Res 1997; 57: 4249-4256
20. Halliday JA, Franks AH, Ramsdale TE, Martin R, Palant E. A rapid, semi-automated method for detection of Galbeta1-4GlcNAc alpha2,6-sialyltransferase (EC 2.4.99.1) activity using the lectin Sambucus nigra agglutinin. Glycobiology 2001; 11: 557-564
21. Dall'Olio F, Chiricolo M. Sialyltransferases in cancer. Glycoconj J 2001; 18: 841-850
22. Cao Y, Merling A, Crocker PR, Keller R, Schwartz-Albiez R. Differential expression of beta-galactoside alpha2,6 sialyltransferase and sialoglycans in normal and cirrhotic liver and hepatocellular carcinoma. Lab Invest 2002; 82: 1515-1524
23. Dall'Olio F, Chiricolo M, D'Errico A, Gruppioni E, Altimari A, Fiorentino M, Grigioni WF. Expression of beta-galactoside alpha2,6 sialyltransferase and of alpha2,6-sialylated glycoconjugates in normal human liver, hepatocarcinoma, and cirrhosis. Glycobiology 2004; 14: 39-49
24. Svensson EC, Conley PB, Paulson JC. Regulated expression of alpha 2,6-sialyltransferase by the liver-enriched transcription factors HNF-1, DBP, and LAP. J Biol Chem 1992; 267: 3466-3472
25. Lise M, Belluco C, Perera SP, Patel R, Thomas P, Ganguly A. Clinical correlations of alpha2,6-sialyltransferase expression in colorectal cancer patients. Hybridoma 2000; 19: 281-286
26. Kaneko Y, Yamamoto H, Kersey DS, Colley KJ, Leestma JE, Moskal JR. The expression of Gal beta 1,4GlcNAc alpha 2,6 sialyltransferase and alpha 2,6-linked sialoglycoconjugates in human brain tumors. Acta Neuropathol (Berl) 1996; 91: 284-292